Project CBD

MAY 3, 2023

Goldstein will be leading the Medical Practicum at CannMed 2023 (May 15-17), where she will also be speaking about CBG and other minor cannabinoids during the main session. You have said that cannabigerol, or CBG, is one of your favorite cannabinoids. Is that because CBG is a precursor for the other plant cannabinoids?

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

DECEMBER 1, 2021

Cannabis and Life Sciences Company Initiates Internal Study Comparing Anti-Inflammatory Properties of Candidate JUVA-019 When Combined With Cannabinoids Such as THC and CBD. who has an extensive background in pharmaceutical research and development. November 30, 2021 04:00 ET | Source: Juva Life Inc.

Cannabinoids 52

Cannabinoids Research and Development Pharmaceutical THC 52

Cannabis Law Report

NOVEMBER 12, 2021

THE Chairman of a recently-listed UK pharmaceutically-focused cannabis company has stood down after a breach of market rules. Neil Mahapatra is a co-founder of the Oxford Cannabinoid Technologies (OCT) which floated on the LSE in the May this year, he is also founder of UK venture capital business Kingsley Capital Partners (KCP).

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. Epidyolex has been approved as a treatment option for children as young as two with Lennox-Gastaut syndrome or Dravet syndrome – difficult-to-treat conditions that can cause multiple seizures a day. ” Source BBC: [link].

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

FEBRUARY 1, 2022

New softgel capsule products further expand ZYUS’ medical cannabinoid offerings and provide patients a precise method for dosing. The launch of these two new softgel products marks another important milestone in ZYUS’ mission to elevate cannabinoids as a standard of care and leverage their transformational potential.

Cannabinoids 52

Cannabinoids Patients Research and Development Media 52

Cannabis Law Report

NOVEMBER 17, 2021

Launch of Zylem ™ 20:1 further expands ZYUS product offerings with new cannabinoid formulation. The launch of this formulation marks an important milestone in ZYUS’ mission to elevate cannabinoids as a standard of care and leverage their transformational potential.

Cannabinoids 52

Cannabinoids Patients Research and Development Extraction 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. Chris Chapman, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

FloridaMarijuana.net

AUGUST 15, 2018

Evidence-based Complementary and Alternative Medicine published an article titled “Post-Traumatic Stress Disorder: Evidence-Based Research for the Third Millennium” which describes how profound the symptoms of PTSD can be: “Traumatic events are profoundly stressful. Women tend to experience different traumas than men.

Treatment 182

Treatment Marijuana Research and Development Therapy 182

CannaMD

FEBRUARY 19, 2020

Post-traumatic stress disorder (PTSD) is a condition most often associated with military veterans, but it is not confined to wartime experiences. Medical Marijuana: More Effective Than Pharmaceuticals? To date, there is no pharmaceutical product targeted specifically for the treatment of PTSD.

CBD 92

CBD Pharmaceutical Research and Development Conditions 92

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. About InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JANUARY 16, 2020

Devonian” or the “Corporation”) (TSXv:GSD), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, announced today the signature of a lease Agreement with Hzb Pharma Canada Inc. Tweet this.

Extraction 64

Extraction Pharmaceutical Research and Development Terpenes 64

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug. Logo – [link].

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Project CBD

FEBRUARY 28, 2023

sativa do not naturally contain cannabinoids, but they can become contaminated with CBD from other plant parts during processing. Available at: www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd. phosphorus, potassium, and calcium). 2 The seeds of C. 2021.108680.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

AUGUST 14, 2021

This partnership marks Mary AG’s first application of farm-level technology, taking its knowledge in automated systems and applying that expertise to a holistic, controlled growing condition that incorporates automated plant health assessment. Working with CBDer on potential non-China greenhouse projects.

Hemp 105

Hemp Supply Chain Cannabinoids Extraction 105

Cannabis Law Report

NOVEMBER 23, 2019

for the production R&D of pharmaceutical grade standardised cannabis. Here the company shares their evolution with Health Europa, exploring the production of pharmaceutical grade standardised cannabis. KANNABEIRA® is a project and a registered trademark under the company Green Donation, Ltd. KANNABEIRA and standardised cannabis.

Pharmaceutical 45

Pharmaceutical Research and Development Cultivation Environment 45

The Cannigma

OCTOBER 9, 2021

Studies demonstrate that cannabis and its cannabinoid constituents have an implication on human urinary function. The common understanding is that every individual has a separate and different reaction to cannabinoid-based therapy, the same is true with how it might influence individual urinary symptoms.

Cannabinoids 86

Cannabinoids Consumption Patients Cannabis 86

Veriheal

MAY 4, 2022

This adds to the growing body of evidence that occasional marijuana use and cardiovascular disease events and markers of subclinical atherosclerosis are not associated,” explained the researchers. On the other end of the spectrum, ingestion (edibles) is considered to be the least harmful way of filling up on cannabinoids.

Research and Development 98

Research and Development Consumption Vaping Edibles 98

Cannabis Law Report

JUNE 10, 2021

Alexis Abraham , Cellular Goods Chief Executive Officer, said: “Successful products start with the best ingredients and being able to source consistent, highly-pure cannabinoids via cellular agriculture from a trusted provider like Willow is essential to our business. ” About Cellular Goods PLC. Cellular Goods is a U.K.-based

Research and Development 66

Research and Development Cannabinoids Pharmaceutical Policy 66

The Joint Blog

JUNE 2, 2020

According to a new study published in the European Journal of Pain, delivering a precise doses of THC via a specialized inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions. Adverse events were mostly mild and resolved spontaneously.

Chronic Pain 58

Chronic Pain Clinical Trials Safety Marijuana 58

Cannabis Law Report

SEPTEMBER 27, 2021

Jodi Brichan is a commercialization expert with more than 25 years of experience in bringing new products to market in hypergrowth healthcare industries such as pharmaceuticals, medical devices, energy devices, and life sciences.

Research and Development 52

Research and Development Pharmaceutical Business Events 52

Cannabis Law Report

FEBRUARY 3, 2022

Nimbus Health is a privately owned, licensed pharmaceutical wholesaler from Germany focusing on medical cannabis in Germany. The closing of the transaction is subject to customary closing conditions. with growth of ~25% in 2021 compared to 2020 and a CAGR of ~55 % since 2017, making Germany one of the largest markets in Europe.

Pharmaceutical 52

Pharmaceutical Events Patients Medicine 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Since cannabinoids, including CBD, share metabolic pathways with other drugs, and have similar mechanisms of action with other drugs, the potential for interaction exists.

CBD 98

CBD THC Conditions Medicine 98

SpeedWeed

MARCH 13, 2021

Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. Preclinical evidence suggests that cannabinoids could be widely beneficial to neurodegenerative diseases, including PD.”. After analyzing the data, the researchers found that 24.5%

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

AUGUST 25, 2021

Founded in 2020, Lucid is developing novel molecules and combinations with the goal of addressing Total Brain Health and targeting some of the most challenging neurodegenerative diseases, such as Multiple sclerosis, and other Brain conditions. million) in FSD Pharma stock (the “ Transaction ”), as further described below.

Clinical Trials 111

Clinical Trials Research and Development Therapy Conditions 111

Cannabis Law Report

AUGUST 23, 2021

FDA has not reviewed the manufacturing process of these unapproved CBD-containing drug products, so the manufacturing conditions of, or contaminant levels in, these products is unknown. Practicing veterinarians face a barrage of questions from pet owners about the use of CBD animal products for conditions ranging from arthritis to anxiety.

Pets 105

Pets Hemp CBD Food 105

Cannabis Law Report

FEBRUARY 2, 2022

Cannabis represents a potential cornucopia of medicinal and pharmaceutical advancement. Cannabis produces over 550 different phytochemicals, over 120 of which are cannabinoids like THC and CBD. Other cannabinoids like Varins (CBGV, THCV, and CBDV) are less well known and potentially offer significant value. BILLERICA, Mass.,

Extraction 52

Extraction Pharmaceutical Hemp Cultivation 52

Puff Puff Post

SEPTEMBER 16, 2019

This new initiative developed by Santé Cannabis equips physicians with the most up-to-date clinical guidelines, support networks, online and in-person training opportunities so they can prescribe and monitor cannabinoid treatment plans with confidence. Event details below: Date: Tuesday, September 17th 2019. Time: 9:00AM to 5:00PM.

Programs 108

Programs Research and Development Education Treatment 108

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov. About INM-755.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

OCTOBER 12, 2021

Their audacious vision to reimagine traditional pharma efficacy trials promises to rapidly and accurately determine which nutraceuticals and natural molecules actually work for which conditions,” said Diamandis. Radicle Real World Sleep results will be announced in early 2022. “We

Clinical Trials 52

Clinical Trials Research and Development Sleep Cannabinoids 52

Cannabis Law Report

APRIL 28, 2019

Does mixing cannabinoids into tobacco make for a safer cigarette? According to US Patent and Trademark Office documents, Vireo intends to market the cannabinoid-infused products as safer alternatives to traditional tobacco. Multistate medical cannabis producer Vireo Health seems to think it does. Reports Leafly. Making A Spliff.

Research and Development 59

Research and Development Cannabinoids Recreational Events 59

Puff Puff Post

SEPTEMBER 24, 2019

the Emperor Shen Nung prescribed cannabis for various medical conditions such as gout, rheumatism, and poor memory. includes the use of cannabis for treating inflammatory conditions. . The human body showed significant evidence of harboring specific receptors, aptly known as cannabinoid receptors. In 2723 B.C.,

History 94

History Cannabinoids Indica Tincture 94

Cannabis Law Report

JULY 22, 2019

Located in Toronto , Truverra is a private cannabis company, serving the Canadian and international cannabis markets through its wholly-owned subsidiaries, Canadian Clinical Cannabinoids Inc. (“CCC”) and Truverra ( Europe ) B.V. (“Truverra Europe”). Conditions to close. ” Transaction Highlights.

Legalization 40

Legalization Research and Development Extraction Pharmaceutical 40

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Since cannabinoids, including CBD, share metabolic pathways with other drugs, and have similar mechanisms of action with other drugs, the potential for interaction exists.

CBD 52

CBD THC Conditions Medicine 52